BioCentury on BioBusiness, Strategy
Gilead bets $11B it can make Pharmasset's PSI-7977 the tenofovir of HCV
Related tables, figures and sidebars
Gilead's second-strike nuc
By Michael Flanagan
Senior Writer
Published on Monday, December 5, 2011
Gilead
Sciences Inc. is betting it can recreate the success it has had with a
nucleotide analog in HIV by making Pharmasset
Inc.'s PSI-7977 the tenofovir of the HCV space.
Gilead turned its first profit
in 2003 based largely on the commercial success of Viread tenofovir, a
nucleotide analog prodrug reverse transcriptase inhibitor approved in 2001 to
treat HIV.
59 words displayed of 1974 words total.
Get the Full Text...
All contents Copyright © 1993-2012 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Purchase This Article
Learn what you're missing.
Broaden your Knowledge Base
The BioCentury Publications Package provides the essential coverage and analysis required by global biopharma decision makers.
Take advantage of our free trials and discover why BioCentury is the choice of biopharma professionals around the globe.
Free Trials Begin the Week Following Sign-up
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your records.
close [ X ]